|
Feb 28
|
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
|
|
Feb 15
|
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
|
|
Jan 4
|
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
|
|
Jan 3
|
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
|
|
Nov 5
|
Applied Therapeutics, Inc. (NASDAQ:APLT) is definitely on the radar of institutional investors who own 38% of the company
|
|
Nov 2
|
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
|
|
Aug 11
|
We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
|
|
Aug 10
|
Applied Therapeutics Reports Second Quarter 2023 Financial Results
|